Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring immunogenicity of SARS-CoV-2 vaccination in Dutch middle-aged and older adults
NL-OMON54058Phase 4Completed
- Sponsor
- Ministry of Health, Welfare and Sport
- Start
- Mar 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccines in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ministry of Health, Welfare and Sport. Primary endpoint: Spike-protein-specific antibody levels after second vaccination and boosters. Started Mar 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccines
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54058.